The KINECT-HD study is investigating valbenazine for the treatment of chorea associated with Huntington disease (HD). Valbenazine has been approved by the United States Food and Drug Administration (FDA) in April 2017 for the treatment of adults with tardive dyskinesia (TD), under the trade name INGREZZA®.
KINECT-HD is a Phase 3, randomized, double-blind, placebo-controlled study. The objectives of KINECT-HD are to:
-Evaluate the efficacy of valbenazine to reduce chorea associated with HD
-Evaluate the safety and tolerability of valbenazine in subjects with HD
-Evaluate the ability of wearable movement sensors to detect changes in physical activity (optional activity)
Status: Currently recruiting.
Study Type: Phase III Clinical Trial
Location: Neurocrine Clinical Site, UBC
Vancouver, BC V6T 2B5
If you are interested in participating in KINECT-HD, please contact the HSG to be connected to a site nearest to you. Study center personnel will determine your eligibility to participate in the KINECT-HD study.
Call Toll-Free (North America): 800-487-7671